NUVB
Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology · US
$6.81
+0.59%1
Insider buys (3m)
4
Insider sells (3m)
-$2.0M
Net value (3m)
+40.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | Hattersley Gary · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 100,000 | $1.87 |
| Aug 21, 2026 | Hattersley Gary · officer: CHIEF SCIENTIFIC OFFICER | Sale | 100,000 | $7.09 |
| Jul 17, 2026 | Sauvage Philippe · officer: Chief Financial Officer | M-Exempt | 1 | $1.97 |
| Jul 17, 2026 | Sauvage Philippe · officer: Chief Financial Officer | M-Exempt | 39,999 | $2.17 |
| Jun 24, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | M-Exempt | 63,000 | $2.93 |
| Jun 24, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | Sale | 63,000 | $6.02 |
| Jun 24, 2026 | Sauvage Philippe · officer: Chief Financial Officer | M-Exempt | 47,668 | $2.17 |
| Jun 24, 2026 | Sauvage Philippe · officer: Chief Financial Officer | Sale | 47,668 | $6.01 |
| Jun 24, 2026 | Markel Stacy · officer: CHIEF PEOPLE OFFICER | M-Exempt | 90,380 | $1.87 |
| Jun 24, 2026 | Markel Stacy · officer: CHIEF PEOPLE OFFICER | M-Exempt | 34,620 | $1.74 |
| Jun 24, 2026 | Markel Stacy · officer: CHIEF PEOPLE OFFICER | Sale | 125,000 | $6.03 |
| Jun 11, 2026 | Mashal Robert · director | Purchase | 25,000 | $4.73 |
| May 26, 2026 | Bazemore Robert B · director | A-Award | 123,397 | $4.79 |
| May 26, 2026 | Cui Xiangmin · director | A-Award | 123,397 | $4.79 |
| May 26, 2026 | Cui Xiangmin · director | A-Award | 76,923 | $5.91 |
| May 26, 2026 | VERNON W ANTHONY · director | A-Award | 123,397 | $4.79 |
| May 26, 2026 | Mashal Robert · director | A-Award | 123,397 | $4.79 |
| May 26, 2026 | BLICKENSTAFF KIM D · director | A-Award | 123,397 | $4.79 |
| May 26, 2026 | FALBERG KATHRYN E · director | A-Award | 123,397 | $4.79 |
| Apr 21, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | M-Exempt | 36,750 | $2.93 |
| Apr 21, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | Sale | 36,750 | $5.01 |
| Apr 21, 2026 | Liu Dongfang · officer: CHIEF MEDICAL OFFICER | M-Exempt | 50,000 | $1.94 |
| Apr 21, 2026 | Liu Dongfang · officer: CHIEF MEDICAL OFFICER | Sale | 50,000 | $5.02 |
| Apr 8, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | M-Exempt | 100,000 | $1.87 |
| Apr 8, 2026 | Wentworth Kerry · officer: CHIEF REGULATORY OFFICER | Sale | 200,000 | $4.52 |
| Mar 3, 2026 | Makunje Moses · officer: SEE REMARKS | A-Award | 224,439 | $5.91 |
| Mar 3, 2026 | Liu Dongfang · officer: CHIEF MEDICAL OFFICER | A-Award | 748,130 | $5.91 |
| Mar 3, 2026 | Hung David · director, 10 percent owner, officer: PRESIDENT AND CEO | A-Award | 1,995,012 | $5.91 |
| Mar 3, 2026 | Hanley David C. · officer: CHIEF TECHNICAL OPERATIONS | A-Award | 748,130 | $5.91 |
| Mar 3, 2026 | Hattersley Gary · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 748,130 | $5.91 |
Institutional positioning
13F filings over the trailing two quarters
New 87Increased 202Reduced 115Sold out 29
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 52,230,295 | Aug 13, 2026 |
| FMR LLC | Increased | 51,989,593 | May 15, 2026 |
| BlackRock, Inc. | Increased | 27,630,837 | Aug 7, 2026 |
| DECHENG CAPITAL LLC | Unchanged | 25,954,439 | May 13, 2026 |
| Decheng Capital LLC | Unchanged | 25,954,439 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 25,100,374 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 11,919,514 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 11,626,198 | May 15, 2026 |
| OMEGA FUND MANAGEMENT, LLC | Unchanged | 8,081,089 | May 15, 2026 |
| Omega Fund Management, LLC | Unchanged | 8,081,089 | Aug 14, 2026 |
| LAURION CAPITAL MANAGEMENT LP | Reduced | 7,822,638 | May 14, 2026 |
| Laurion Capital Management LP | Reduced | 7,820,013 | Aug 13, 2026 |
| UBS Group AG | Increased | 7,491,586 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 7,370,794 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 6,784,927 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 21, 2026